SGLT2 inhibitors in the management of type 2 diabetes

被引:65
作者
Reddy, R. P. Monica [1 ]
Inzucchi, Silvio E. [2 ]
机构
[1] Griffin Hosp, Dept Med, Derby, CT USA
[2] Yale Sch Med, Endocrinol Sect, Dept Med, New Haven, CT 06510 USA
关键词
SGLT2; inhibitors; Type 2 diabetes mellitus; Antihyperglycemic therapy; INADEQUATE GLYCEMIC CONTROL; FAMILIAL RENAL GLUCOSURIA; DOUBLE-BLIND; CARDIOVASCULAR OUTCOMES; JAPANESE PATIENTS; ADD-ON; EUROPEAN ASSOCIATION; POSITION STATEMENT; BODY-WEIGHT; FAT MASS;
D O I
10.1007/s12020-016-0943-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The glucose-lowering pharmacopeia continues to grow for patients with type 2 diabetes. The latest drug category, the SGLT2 inhibitors reduce glycated hemoglobin concentrations by increasing urinary excretion of glucose. They are used mainly in combination with metformin and other antihyperglycemic agents, including insulin. Their glucose-lowering potency is modest. Advantages include lack of hypoglycemia as a side effect, and mild reduction in blood pressure and body weight. Side effects include increased urinary frequency, owing to their mild diuretic action, symptoms of hypovolemia, genitourinary infections. There are also recent reports of rare cases of diabetic ketoacidosis occurring in insulin-treated patients. Recently, a large cardiovascular outcome trial reported that a specific SGLT2 inhibitor, empagliflozin, led to a reduction in the primary endpoint of major cardiovascular events. This effect was mainly the result of a surprising 38 % reduction in cardiovascular death, and the drug was also associated with nearly as large a reduction in heart failure hospitalization. These findings were notable because most drugs used in type 2 diabetes have not been shown to improve cardiovascular outcomes. Accordingly, there is growing interest in empagliflozin and the entire SGLT2 inhibitor class as drugs that could potentially change the manner in which we approach the management of hyperglycemia in patients with type 2 diabetes.
引用
收藏
页码:364 / 372
页数:9
相关论文
共 51 条
[1]  
[Anonymous], TXB MED PHYSL
[2]   Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial [J].
Bailey, Clifford J. ;
Gross, Jorge L. ;
Hennicken, Delphine ;
Iqbal, Nayyar ;
Mansfield, Traci A. ;
List, James F. .
BMC MEDICINE, 2013, 11
[3]   Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications [J].
Bakris, George L. ;
Fonseca, Vivian A. ;
Sharma, Kumar ;
Wright, Ernest M. .
KIDNEY INTERNATIONAL, 2009, 75 (12) :1272-1277
[4]   Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo [J].
Bentley-Lewis, Rhonda ;
Aguilar, David ;
Riddle, Matthew C. ;
Claggett, Brian ;
Diaz, Rafael ;
Dickstein, Kenneth ;
Gerstein, Hertzel C. ;
Johnston, Peter ;
Kober, Lars V. ;
Lawson, Francesca ;
Lewis, Eldrin F. ;
Maggioni, Aldo P. ;
McMurray, John J. V. ;
Ping, Lin ;
Probstfield, Jeffrey L. ;
Solomon, Scott D. ;
Tardif, Jean-Claude ;
Wu, Yujun ;
Pfeffer, Marc A. .
AMERICAN HEART JOURNAL, 2015, 169 (05) :631-U75
[5]   Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin [J].
Bolinder, J. ;
Ljunggren, O. ;
Johansson, L. ;
Wilding, J. ;
Langkilde, A. M. ;
Sjostrom, C. D. ;
Sugg, J. ;
Parikh, S. .
DIABETES OBESITY & METABOLISM, 2014, 16 (02) :159-169
[6]   Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin [J].
Bolinder, Jan ;
Ljunggren, Osten ;
Kullberg, Joel ;
Johansson, Lars ;
Wilding, John ;
Langkilde, Anna Maria ;
Sugg, Jennifer ;
Parikh, Shamik .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) :1020-1031
[7]   Familial renal glucosuria:: SLC5A2 mutation analysis and evidence of salt-wasting [J].
Calado, J ;
Loeffler, J ;
Sakallioglu, O ;
Gok, F ;
Lhotta, K ;
Barata, J ;
Rueff, J .
KIDNEY INTERNATIONAL, 2006, 69 (05) :852-855
[8]   Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus [J].
Cherney, David Z. I. ;
Perkins, Bruce A. ;
Soleymanlou, Nima ;
Maione, Maria ;
Lai, Vesta ;
Lee, Alana ;
Fagan, Nora M. ;
Woerle, Hans J. ;
Johansen, Odd Erik ;
Broedl, Uli C. ;
von Eynatten, Maximilian .
CIRCULATION, 2014, 129 (05) :587-597
[9]  
Chilton R., 2015, J HYPERTENS S1, V33, pe53, DOI [10.1097/01.hjh.0000467486.05191.41, DOI 10.1097/01.HJH.0000467486.05191.41]
[10]   Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus [J].
Davies, M. J. ;
Trujillo, A. ;
Vijapurkar, U. ;
Damaraju, C. V. ;
Meininger, G. .
DIABETES OBESITY & METABOLISM, 2015, 17 (04) :426-429